His past forecast on 3 Sept 13 was a bit suspect when (just before our beloved ADCOM) he opened his rating of AMRN as "BUY" with a PT of $15!! Since then he has been "HOLD" with lower targets. Until now.
This two day move can't be based on one analyst at Sun Trust . Too much volume, and staying power. Something else is partially driving this . The sixty-four dollar question is what ?
STS, without getting into the details of why Mr. Boris referenced 2020 estimates in his analysis, I would like you to look at the bottom of page 9 of the report. It notes that all price targets are on twelve-month terms unless otherwise noted. I do not believe Mr. Boris tried to portray the six dollars as anything other than a 12 month target. Traditionally all analyst have price targets that are on a 12 to 18 month basis. Having a five-year target would be stupid and idiotic on his part. Moreover I believe he has racist target because all of the catalyst for now within a 12 to 18 month window which makes sense for the upgrade.
Price target is for 12-18 months out...upgraded revenue projection is for 2020 as a basis for that price target
Rocks for brains? At least he knew about Par GL. He made some verry interesting points. It's practically an advertisement for V...
"...Our Vascepa (pure EPA) revenue ramp due to its superior profile, competitive price point compared to inferior branded/generic Lovaza"
"..Tier Two expansion as PBMs drop Lovaza from coverage in 2015.."
"..inferior Rx fish oil Lovaza…
….Vascepa’s value proposition to payors/PBMs is compelling compared to its competitors due to its superior clinical profile…."
As to recent price action
..."Could be that the 8 million $1.50 warrents are going to get exercized and AMRN would get $12 million..." OR....the exercise period won't be extended beyond Feb.27...meaning no need for add'l capital and no 8 million share dilution..????
News 
Market Data 
Discover 
AI
